TESARO (NASDAQ:TSRO) was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued on Friday.

Other equities research analysts have also issued research reports about the company. HC Wainwright cut their target price on TESARO to $71.00 and set a “buy” rating on the stock in a research report on Friday, July 20th. Citigroup cut their price target on TESARO from $100.00 to $85.00 and set a “buy” rating on the stock in a report on Wednesday, August 29th. Cann reiterated a “buy” rating and issued a $83.00 price target on shares of TESARO in a report on Tuesday, September 4th. Guggenheim initiated coverage on TESARO in a report on Monday, September 17th. They issued a “buy” rating on the stock. Finally, ValuEngine upgraded TESARO from a “hold” rating to a “buy” rating in a report on Friday, October 12th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. TESARO has an average rating of “Buy” and an average target price of $78.42.

Shares of TESARO stock opened at $42.98 on Friday. TESARO has a one year low of $25.62 and a one year high of $119.00. The company has a debt-to-equity ratio of -29.71, a quick ratio of 3.64 and a current ratio of 4.11. The stock has a market cap of $2.14 billion, a P/E ratio of -4.69 and a beta of 1.00.

TESARO (NASDAQ:TSRO) last announced its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($3.04) EPS for the quarter, missing the consensus estimate of ($2.66) by ($0.38). TESARO had a negative net margin of 180.29% and a negative return on equity of 285.30%. The business had revenue of $57.21 million for the quarter, compared to the consensus estimate of $65.50 million. During the same quarter in the previous year, the company earned ($2.82) EPS. The firm’s revenue for the quarter was up 94.2% on a year-over-year basis. Equities research analysts expect that TESARO will post -11.12 earnings per share for the current fiscal year.

In other TESARO news, Director Arnold L. Oronsky sold 10,000 shares of the stock in a transaction that occurred on Tuesday, August 7th. The stock was sold at an average price of $26.77, for a total value of $267,700.00. Following the transaction, the director now owns 12,479 shares in the company, valued at $334,062.83. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders sold 10,630 shares of company stock worth $290,424. Corporate insiders own 33.70% of the company’s stock.

Several institutional investors have recently modified their holdings of TSRO. Skylands Capital LLC purchased a new stake in shares of TESARO in the second quarter worth approximately $182,000. New Jersey Better Educational Savings Trust purchased a new stake in shares of TESARO in the third quarter worth approximately $234,000. Stifel Financial Corp purchased a new stake in shares of TESARO in the first quarter worth approximately $241,000. Janney Montgomery Scott LLC purchased a new stake in shares of TESARO in the second quarter worth approximately $257,000. Finally, BTG Pactual Global Asset Management Ltd purchased a new stake in shares of TESARO in the second quarter worth approximately $277,000.

About TESARO

Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.

Featured Article: What Factors Can Affect Return on Equity?

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.